Menu Search
Equities

ReShape Lifesciences Inc

24O:BER

ReShape Lifesciences Inc

Actions
  • Price (EUR)1,049.80
  • Today's Change1,049.80 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024 07:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.

  • Revenue in USD (TTM)8.05m
  • Net income in USD-9.02m
  • Incorporated2008
  • Employees31.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RSLS:NAQ since
announced		Transaction
value
Vyome Therapeutics IncAnnounced09 Jul 202409 Jul 2024Announced-52.28%--
Data delayed at least 15 minutes, as of Nov 13 2024 20:13 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.